Survey: 85 percent of lifescience professionals concerned about impact of differing AI regulations on cross-border collaboration
The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has announced the results of a global survey in conjunction with CCC (Copyright Clearance Center), a leader in advancing copyright, accelerating knowledge, and powering innovation, on the impact of AI and copyright legislation on pharma R&D. While 83% of life science professionals are now using generative AI in their research, there is still widespread concern about the impact of differing AI regulations on cross-border research collaboration (85%). Additionally, 42% of respondents said they don’t think about copyright before sharing or using third-party information with AI tools. The survey was conducted at the Alliance’s annual US conference held this year in Philadelphia, which gathered more than 200 industry experts to collaborate on topics such as AI regulation, harmonization of data standards, and patient-centricity.
“It’s encouraging to see such an uptake in the number of researchers using Generative AI to accelerate R&D, but it’s a concern that copyright is often an afterthought. Less than half (40%) of organizations have a team or person dedicated to understanding copyright issues and AI, even though this is a complex area that requires expertise,” said Babis Marmanis, CCC Executive Vice President & CTO. “
“AI is fast becoming commonplace in R&D, yet a fifth of researchers are still not using the technology. The best way to overcome any lingering adoption hurdles is together. We must ensure those remaining researchers have the confidence and expertise to use AI safely, so they can accelerate discovery, and enable better outcomes for patients,” commented Dr Becky Upton, president of The Pistoia Alliance. “Whether it’s copyright compliance, broader AI regulation ambiguities, or data standardization, the Alliance is committed to launching projects that will deliver a tangible impact to the life science industry. As 2025 approaches, we are keen for new project suggestions and are looking forward to broadening the Alliance’s reach even further, with more research and projects, and involving more global regulatory agencies in our communities.”
Source: Pistoia Alliance
The post Survey: 85 percent of lifescience professionals concerned about impact of differing AI regulations on cross-border collaboration appeared first on PharmaLive.
{Categories} _Category: Implications{/Categories}
{URL}https://www.pharmalive.com/survey-85-percent-of-lifescience-professionals-concerned-about-impact-of-differing-ai-regulations-on-cross-border-collaboration/{/URL}
{Author}Administrator{/Author}
{Image}{/Image}
{Keywords}Therapeutics,artificial intelligence,regulations{/Keywords}
{Source}Implications{/Source}
{Thumb}{/Thumb}